Role of Luminex in HLA Qualitative Testing for Transplantation Medicine

Clinical Applications in Transplantation

The American Journal of Transplantation recommends post-transplant monitoring of donor-specific antibodies (DSAs) with a strength of evidence of 1B for kidney, heart, and lung transplantation in cases of allograft dysfunction 2
High-resolution HLA genotyping through Luminex is recommended (1A for kidney, 1B for heart/lung) for correct assessment of anti-HLA antibody specificity to donor 2
Luminex helps identify patients at risk for antibody-mediated rejection (ABMR) by detecting DSAs that may not be identified by less sensitive methods 1
The technology provides comprehensive assessment of multiple HLA loci simultaneously, including HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, and -DPB1 3

Integration of anti-HLA antibody testing with clinical, functional, and histologic parameters is recommended (1B for kidney, 1C for heart/lung) to evaluate allograft prognosis 2, 4
Repeated measures of anti-HLA antibody testing are valuable to appreciate antibody kinetics post-transplant (1C for kidney) 2

Further studies are needed to demonstrate the clinical utility and cost-effectiveness of high-resolution genotyping for correct assessment of anti-HLA antibody specificity 5
Development of standardized approaches to using HLA epitope/eplet mismatch scores with rigorous clinical validation across cohorts and organs is an important next step 5